Conflicting signals on US accelerated approvals

被引：3
|
作者：
Fox, JL
机构：
来源：
NATURE BIOTECHNOLOGY | 2005年 / 23卷 / 09期
关键词：
D O I：
10.1038/nbt0905-1027
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The results of a phase 3 clinical study on the lung cancer drug Iressa (gefitinib) have revealed that the drug did not produce a significant survival advantage over placebo. Since then some FDA critics contend that the accelerated review process should be slowed, whereas others fear that heightened anxieties about safety could undermine a program that provides therapeutics more quickly to needy patients.
引用
收藏
页码：1027 / 1028
页数：2
相关论文
共 50 条
  • [41] Infants' use of conflicting emotion signals
    Barrett, KC
    Campos, JJ
    Emde, RN
    COGNITION & EMOTION, 1996, 10 (02) : 113 - 135
  • [42] Discrepancy in accelerated approvals for cancer drugs in the United States and Europe
    Nierengarten, Mary Beth
    CANCER, 2024, 130 (01) : 8 - 9
  • [43] Accelerated approvals: Early-phase success or premature authorization?
    Mao, Xiangyun
    Alexander, Caleb
    Li, Guanqiao
    CANCER CELL, 2024, 42 (11) : 1799 - 1802
  • [44] Project Confirm: Accelerated Drug Approvals for CML-Letter
    Beumer, Jan H.
    Salamone, Salvatore J.
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 235 - 236
  • [45] Project Confirm: Accelerated Drug Approvals for CML-Response
    Sweet, Kendra L.
    Cortes, Jorge E.
    Apperley, Jane F.
    Mann, Mel
    Mauro, Michael J.
    Oehler, Vivian G.
    Ruiz, Cristina
    Schiffer, Charles A.
    Ehrlich, Lori A.
    Pamuk, Gulsum E.
    Wynne, Joseph
    Mehta, Gautam U.
    Okusanya, Olanrewaju O.
    de Claro, R. Angelo
    Theoret, Marc R.
    Smith, B. Douglas
    Norsworthy, Kelly J.
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 237 - 238
  • [46] Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia
    Sweet, Kendra L.
    Cortes, Jorge E.
    Apperley, Jane F.
    Mann, Mel
    Mauro, Michael J.
    Oehler, Vivian G.
    Ruiz, Cristina
    Schiffer, Charles A.
    Ehrlich, Lori A.
    Pamuk, Gulsum E.
    Wynne, Joseph
    Mehta, Gautam U.
    de Claro, R. Angelo
    Theoret, Marc R.
    Smith, B. Douglas
    Norsworthy, Kelly J.
    CLINICAL CANCER RESEARCH, 2023, 29 (12) : 2179 - 2183
  • [47] US Congress probes industry influence on chemical approvals
    Erickson, Britt
    CHEMICAL & ENGINEERING NEWS, 2021, 99 (31) : 15 - 15
  • [48] US DRUG AND BIOLOGIC PRODUCT APPROVALS DURING 1993
    BEARY, JF
    EATEN, CR
    COPMANN, TL
    WIERENGA, DE
    DRUG DEVELOPMENT RESEARCH, 1994, 32 (03) : 127 - 133
  • [49] Recent milestone US ophthalmic product approvals and clearances
    Novack, Gary D.
    OCULAR SURFACE, 2018, 16 (04): : 487 - 491
  • [50] Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals
    Hakariya, Hayase
    Moriarty, Frank
    Ozaki, Akihiko
    Mulinari, Shai
    Saito, Hiroaki
    Tanimoto, Tetsuya
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (07):
12345